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1. Introduction 
Each meal reminds us of our energy needs. As heterotrophs, we have a whole set of organs 
for food digestion and conversion into substances usable by our body. The breakdown of 
food (mainly proteins, carbohydrates and lipids) takes place in the gastrointestinal tract 
(GIT) which assimilates these elements and transfers them into the bloodstream. In a 
simplified manner, these digestion and absorption functions are provided by the following 
organs: the mouth, oesophagus, stomach, the small intestine (including the duodenum, 
jejunum and ileum), the large intestine or colon (formed from the right, transverse and left 
colon), ending with the rectum and anus. Various functions are required to facilitate the 
hydrolysis of food. They include a combination of physical factors (temperature, pH, 
grinding and friction, ...), chemical factors (acid secretions, bile salts, ...) and enzymes 
(salivary, gastric or pancreatic enzymes,…). Colonic physiology also benefits in parallel 
from a real contribution by micro-organisms, specifically bacteria. 
Several factors contribute to our interest in the human digestive tract. For example, in 
Europe colorectal cancer is the second cause of cancer in women and the  third in men  
(Boyle & Ferlay, 2005). Some pathologies can be chronic, infectious or even mortal. The 
digestive tract is also a simple and practical way of giving chemotherapy treatment, whether 
the pathology is of digestive origin or not.  
Proposing more or less advanced simulation systems of the GIT, therefore, can overcome 
certain ethical, technical and/or financial difficulties in research. Furthermore, it is 
interesting to model the way the digestive tract works, in order to test various elements 
independently and/or concomitantly: such as drugs, food/nutrients, microbial agents, even 
physiological and physical elements.  
Animal models work particularly well if they have a similar anatomical/physiological GIT. 
Rodent models, however, are used more in the laboratory for practical reasons. In order to 
enhance the resemblance to humans, "humanized" animal GITs have be developed from 
germ-free, newborn animals turned into gnotobiotic animals after being seeded by a human 
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microbiota (see for example (Samuel & Gordon, 2006). In a more controlled manner, in vitro 
models are also alternatives which may answer biological questions, in an easier, more 
complete and less partial manner. In all cases, however, in vitro-in vivo correlations have to 
be established. 
Our laboratory is particularly involved in the development, elaboration and use of in vitro 
devices able to reproducibly simulate the behaviour of elements in the digestive tract, with 
special emphasis on the human digestive tract. This involves the study of food, medicines, 
prebiotics, probiotics and infectious agents in the digestive tract. In this article we will 
particularly address the workings of the colon and its metabolic and physiological roles 
which still remain largely unknown. We will also present a fermentation system called 
ECSIM (Environmental Control System for Intestinal Microbiota), which is a modular 
system consisting of three reactors from GPC (Global Process Concept, www.gpcbio.com). It 
can be used in various configurations to mimic the different functions of a human colon  
depending on whether a simulation of a portion of the colon (for example, P-ECSIM for a 
simulation of the proximal part) or the colon in its totality and continuity is needed (for 
example, 3S-ECSIM for 3-stages-ECSIM, for the proximal, then transverse, then distal part). 
Figure 1 shows the general principle of the equipment. 
 
 
Fig. 1. A general view of the ECSIM platform permitting the simulation of the human gut. 
Three computer-controlled bioreactors from Global Process Concept (www.gpcbio.com) are 
individually or collectively used as one modular system. 
2. GIT, colon and gut microbiota 
Simulating some or most of the functions of the digestive tract requires an accurate 
knowledge of the components of the GIT, at both the descriptive and functional levels. This 
is particularly true for the colon, which is different anatomically and functionally compared 
3 x
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to the other parts of the GIT. Water and electrolytes are reabsorbed at this level of the tract, 
leading gradually to a solidification of faecal matter all along the colon. It also involves an 
intensive microbial fermentation process: matter which was either only partially digested or 
not at all digested in the upper parts of the GIT (rapid transfer from the upper part 
preventing total digestion, absence of necessary enzymes, limiting physicochemical 
conditions, ...) or finally because these elements do not come from alimentation but from the 
digestive tract itself (digestive secretions like the epithelial mucins, dead bacterial and 
human cells,...).  
There are 3 distinct parts in the colon: the right (or ascending) side consists of the caecum 
and proximal colon; the central transverse colon; and the left side (or descending colon) 
consisting of the distal colon, the sigmoid colon and the rectum.  
An important and specific microbial population inhabits each of these levels, whose density 
is incommensurate  with the previous stages (Table 1), reaching values of 1012 bacteria per 
gram of colonic contents (Savage, 1977). 
 
  
Length 
(cm) 
pH 
Usual 
transit 
time 
(H) 
Microbiota 
abundance 
per gram 
 
Stomach  12 1 – 2.5 2 - 6 0-104  
Small 
intestine 
Duodenum 25 6-6.5  104 – 105  
 Jejunum 160 6.5 3 - 5 105 - 107  
 Ileon 215 7.5  107 – 108  
Large 
intestine 
caecum 6   1010 - 1011 
Matter entering 
the colon 
 
Ascending 
colon 
10 – 15 5.5-6.0  1010 - 1011 (g per day) 
 
Transverse 
colon 
50 6.0-6.5 50 - 70 1010 - 1011 
Polysaccharides 
10-60g 
 
Descending 
colon 
25 6.5-7.0  1010 - 1011 
Proteins 
6-18g 
 
Sigmoid 
colon 
40 – 80   1010 - 1011 
Lipids 
5-8g 
 Rectum 18  1 1010 - 1012  
Table 1. Some physical, physiological and microbial characteristics of the human GIT. 
An estimation of the quantity of matter  entering the large intestine is  given in the column 
on the right (adapted from A. Mihajlovski  and G. Macfarlane & J. Cummings (G.T. 
Macfarlane & Cummings, 1991; A. Mihajlovski, 2010)). 
The term “microbiota” is used to define this set of micro-organisms living together within 
our bodies. The genomes of these “indigenous microbes” are known as the “microbiome”,  
the microbial counterpart of our genome. B. Zhu and his colleagues (Zhu et al., 2010) state 
that this was suggested in 2001 by the Nobel Laureate Joshua Lederberg and by Hooper & 
Gordon (2001). “Microbiome”  can be substituted by the more general term “metagenome” 
when concerned with environmental genomic studies (“metagenomics” (Handelsman, 
2004)). The authors of a recent article did not hesitate to use the terms “human gut 
microbiome” as “the second genome of human body” in their title (Zhu et al., 2010) and  this 
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enthusiasm also accompanies the results of recently obtained gut metagenomics (Qin et al., 
2010).  
In the early 2000s, once the human genome had been decoded, some scientists called for a 
collective effort to study global metagenomics to decode all of the bacterial communities 
inhabiting the human body, from the external communities of the skin, to internal ones, 
such as oral, intestinal and vaginal flora. The creation of a second “human genome 
project” (Relman & Falkow, 2001), studying the whole human flora, would complete our 
knowledge of the human genome. In 2005, the French “National Institute of Agronomic 
Research” (INRA), initiated an international discussion on the opportunity of structuring 
an intestinal microbiota research effort. This led to the creation of the project MetaHIT, 
“Metagenomics of the Human Intestinal Tract”, supported by the Seventh Framework 
Program of the European Union (www.metahit.eu). In parallel, in 2007 the American 
National Institute of Health created the Human Microbiome Project (HMP, 
http://nihroadmap.nih.gov/hmp/). Its purpose was to address not only the intestinal 
tract, but also the skin, mouth and vagina (Peterson et al., 2009). For the intestine, the 
approach was to directly sequence 1,000 bacterial genomes usually found in this habitat, 
and in parallel determine the metagenome of 250 human guts. The results are expected in 
2014. 
2.1 Diversity and repartition of human gut microbiota 
If we take a particular look at the microbes in the colon, a great diversity is observed in 
the part where the microbial density is highest. An overview of the various microbes 
found shows that planktonic forms predominate in the lumen, and biofilms are 
principally encountered on the epithelium. In addition, material in transit, in the process 
of being metabolized, is also colonized by micro-organisms, which move with the matter. 
Because of the gradual disappearance of oxygen along the digestive tract, and a very 
negative redox potential (ORP), the main bacterial populations are facultative or strict 
anaerobic species.  
Before the creation and development of molecular microbial ecology tools, studies were 
based almost entirely on the use of selective or non selective culture media. Such studies 
were completed by biochemical, metabolic and morphological (microscopic examination 
and Gram stain) information. There were large discrepancies, however, between the data 
produced by culture and microbial counts performed by Fluorescent In Situ Hybridization 
(FISH). In fact, studies with DAPI staining (- 4’, 6’-diamidino-2-phenylindole) revealed only 
15% of cultured bacteria were found by counting (Langendijk et al., 1995). Since then, 
numerous molecular methods have been developed to overcome the limitations of microbial 
culture and assess the number of bacterial species in the digestive tract. The first methods 
used were based on the development and sequencing of the clone library of bacterial 16S 
DNA, using techniques that permitted to consider max 50% (even 10%) being cultivated 
species (Ley et al., 2006; Zoetendal et al., 2004).  
It is particularly difficult to precisely define both the concept of species in bacteria and the 
justification of the rules used for these definitions. Molecular methods are used to define 
groups of micro-organisms based on their identity for sequences, principally those of 16S 
RNA considered in part or almost in its entirety. This defines operational taxonomic units 
(OTUs) on the basis of variations of 1, 2, 3 or 5% among these sequences (or 99%, 98%, 
97% or 95% of their identity). It is generally accepted that 98% of the identity used to 
define phylotypes may be related to the concept of species. On this basis, 500 to more than 
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1,000 different species have been detected in the gut microbiota of 3 different individuals 
(Eckburg et al., 2005). M. Rajilić-Stojanović and her colleagues compiled all data available 
up to 2007 in a meta-analysis  and identified 1,200 different phylotypes (Rajilic-Stojanovic 
et al. 2007). Recent technological advances in sequencing technology, such as the 454 
technology of Roche Diagnostics Applied Science or Solexa/Illumina, have facilitated 
inventorying an even larger number of colonic bacteria (Claesson & O'Toole, 2010; 
Murphy et al., 2010; Tasse et al., 2010). D.N. Frank and N.R. Pace used metagenomics data 
to deduce the presence of 15,000 to 36,000 different bacterial species,  with variations due 
to the molecular criteria chosen (Frank & Pace, 2008). It has recently been shown, 
however, that part of the bacteria are universally shared between individuals (Tap et al., 
2009). The work defined a “universal core”, more or less large, depending on the degree 
of sharing among humans. It is important to note that, although the number of non-
cultivable species seems very large in these studies, metagenomics enables a "gene 
catalogue from the human gut microbiome" to be established (Qin et al., 2010). It is 
theoretically possible, therefore, to extrapolate the activity or the metabolic potential of 
microbiota.  
Unfortunately, a very important part of colonic microbiota remains uncultivable as isolated 
species. This can be explained by a particularly high sensitivity to O2, even at low levels of 
exposure (amount, duration), a high dependence on certain elements not present in the 
media being used, and a strong dependence on other microbial species providing such 
elements. It is interesting, therefore, to develop cropping systems which maintain consortia 
in vitro, and allow the study of biological interactions and ecological and functional 
relationships between the various members of the colonic ecosystem. Baoli Zhu et al. (2010) 
indicate that recent results in in vitro systems can detect 50 to 70% of sequences belonging to 
"uncultivated bacteria". This new data makes current vocabulary inappropriate and requires 
a rapid evolution and/or a redefinition of the terms being used. For example, one can 
question the legitimacy of the finality of such terms as “non-cultivable”.  
The role of the bacterial community should not obscure the importance of other micro-
organisms. Two other domains of life which must not be forgotten can be found in this 
ecosystem: eukaryotic cells  (e.g. Blastocystis spp.) and yeasts (e.g. Candida spp.) (Scanlan 
& Marchesi, 2008), and Archaea, which includes methanogens able to synthesize methane 
from CO2 and H2 from the metabolism of other microbiota microorganisms (Mihajlovski, 
Doré, Levenez, Alric, & Brugère, 2010; Strocchi, Furne, Ellis, & Levitt, 1991). Some 
Archaea may also possess other features, closely related, or not,  with non-usual 
methanogens, i.e. potential Thermoplasmatales (Mihajlovski, Alric, & Brugere, 2008; 
Mihajlovski et al., 2010) or halophilic archaea (Oxley et al., 2010). Furthermore, the 
presence of a considerable diversity of viral genotypes is also important, as about 1,200 
have been described to date (Breitbart et al., 2003). This could have a significant functional 
and metabolic implication, not per se, but through the role they play in regulating 
bacterial populations.  
2.2 Properties, functions and evolution of gut microbiota 
It is important to remember that the contribution of intestinal microbiota is a major, though 
not essential, factor in the life of the host (germ-free mice are viable but present various 
alterations). The microbiota acts as a physical barrier to exclude pathogens by coating the 
mucosa and by inducing antimicrobial peptide production by Paneth cells (Hooper et al., 
2003). It also contributes to the maturation, morphology and maintenance of the digestive 
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tract (Hooper et al., 2002), reduces inflammatory response and the number of Peyer's 
patches, and promotes angiogenesis (Stappenbeck et al., 2002). Furthermore, it is responsible 
for the production of available vitamins, especially Vit. B9, Vit. B12 and Vit. K (Hill, 1997) 
and is a source of energy, per se and through its metabolism. For example, germ-free mice 
implanted with a microbiota show a 60% increase in body-fat (Backhed et al., 2004), mainly 
due to the resulting and excess of energy-release from the fermentation of undigested food 
residue. Many other research works are being undertaken to understand the relationships  
linking the microbiota to the regulation of fat storage, or more broadly, how gut microbiota 
may influence metabolism and body composition (Vrieze et al., 2010).  
Microbiota metabolic properties have different functional groups which can be identified 
according to their metabolic capabilities (including the use of substrate), creating 
dependencies and mutualistic relationships between organisms. The colon is, therefore, the 
centre of an intense fermentation activity. The origin of fermented substrates may be due to 
the non-use, partial-use or total-use of food/nutrients in the upper compartments (right part 
of Table 1). This may be caused by the transit time being too rapid and not allowing full 
treatment in the upper parts. Most often though, it is due to the absence of necessary 
enzyme activities and to unfit physicochemical conditions (especially pH). Other substrates, 
such as endogenous substrates, may come from the host itself: for example secreted 
mucopolysaccharides lubricating the digestive tract (mucins), digestive enzymes, cellular 
debris and even microbial debris.  
Less than 100 g of exogenous substrates reaching the colon and available for microbial 
conversion (Cummings & Macfarlane, 1997) can produce 10% of our energy needs through  
their metabolism by the colonic microbiota (G.T. Macfarlane & Cummings, 1991). As 
mentioned in Table 1, these substrates are mostly complex polysaccharides and proteins 
with some lipids and nucleic acids. Out of the 100 g the complex polysaccharides alone 
account for 10 to 60 g. These are the substrates for which metabolic pathways are best 
known. The many different microorganisms and enzymes which provide the first steps of 
microbial conversion (fibrolytic flora) are still being characterized. The contribution of 
multiple microbial groups is necessary at this stage (Figure 2). The hydrolysis of 
polysaccharides by fibrolytic bacteria leads to simple compounds which are, in turn, used 
by each member of the fermentative microbiota to produce pyruvate. Depending on which 
microorganism is present, different reactions will then lead to the formation of lactic acid 
and short chain fatty acids, with over 90% being three major compounds: propionate, 
butyrate and acetate (the last being in amounts two to three times greater than the other 
two). Although synthesis takes place mainly in the ascending part of the colon (main area of 
polysaccharides fermentation), the concentrations observed in humans are nevertheless 
fairly constant (around 120 mM) in the other parts due to a decreasing absorption along the 
large bowel (G. T. Macfarlane, Gibson, & Cummings, 1992). Another consequence of this 
fermentation is the production of gases, particularly CO2 and H2. The presence of the latter 
limits feed-back on the effectiveness of this fermentation. It is necessary, therefore, to 
eliminate the presence of H2, which is realised by hydrogenotrophs. This dedicated 
microbiota is variable among individuals and can eliminate the H2 in 3 different (sometimes 
combined) anaerobic reduction processes: sulfate-reduction (synthesis of H2S from sulfate as 
acceptor of electrons) realised by sulfate-reducing prokaryotes (SRP), reductive acetogenesis 
(reduction by a combination of CO2 and a methyl) realised by acetogens, and 
hydrogenotrophic methanogenesis (CO2 reduction to methane) realised by methanogenic 
archaea. 
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adapted from A. Bernalier-Donadille (2010). 
Fig. 2. A schematic overview of the microbial fermentative metabolism in the human colon 
The properties and functions of the intestinal microbiota are varied, complex and probably 
partly unknown. An in-vitro system, even with its limitations, could provide a simplified 
way of addressing various biological questions and problems. There is, therefore, a need to 
develop in-vitro models allowing a controlled approach to physical, chemical and 
microbiological parameters. As it appears to be extremely difficult to grow a significant part 
of the microbiota, artificially replicating a colon may provide a solution for growing 
microbiota as a consortium, and  make it easier to determine the impact of environmental 
factors (i.e. all that is external to the microbiota) on its composition and metabolism. This 
requires a good knowledge of such environmental conditions in order to replicate them in 
vitro, and to have already measured various biological parameters in vivo in order to 
validate the in vitro results. Table 1 shows some of the results. The parameters vary with the 
specificity of nutrition, age and some diseases. The developed model, therefore, should 
ideally consist of a dynamic, multi-set system, easily adaptable to any simulation 
requirement, physiological or pathological situation. 
3. The ECSIM paradigm 
3.1 Simulating gut fermentations: a rapid overview of existing systems 
Many in vitro systems have been developed to answer biological problems relating to the 
gastrointestinal tract. For example, there are systems to simulate chewing and to 
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reproduce the size of masticated food in the presence of artificial saliva (Woda et al., 
2010). Some tools focus on the digestive kinetics of food and drugs, others are limited to 
the study of in-vitro dissolution [see the various equipments of the pharmacopoeia, USP 1, 
2, 3 and 4 (Pharmacopeia, 2011)] or conversely, to replicate kinetic absorption by simple or 
more complex systems of intestinal cells. In general these systems replicate the different 
compartments of the GIT anatomically and physico-chemically, with or without a 
gradual/discontinuous evolution of the conditions encountered along the digestive tract. 
For example, a simple thermostatic beaker may be sufficient to replicate a basic stomach; a 
highly acidic pH, controlled/modulated in a liquid medium with ions, bile salts, gastric 
enzymes, may be sufficient to control the release kinetics of encapsulated active 
ingredients. The study of colonic fermentation is based on models of varying complexity.  
George & Sandra Macfarlane (G. T. Macfarlane & Macfarlane, 2007) describe the 
motivations for using such systems and the essential features found in these models. 
Generally, these tools range from simple batch cultures to continuous culture systems. 
The choice of the model is based on the advantages/disadvantages of each to respond to 
specific biological problems. Various factors must be taken into account and comparisons 
made relative to the degree of reliability of what actually happens in vivo : for example, 
the ease of experimentation, the amount of experiments (acquisition time and speed), the 
number of environmental factors which need to be controlled (few/many), the price. This 
chapter includes, in our opinion, the three systems most likely to replicate the complexity 
of the colon in a controlled manner.  
The SHIME [Simulator of the Human Intestinal Microbial Ecosystem (Molly et al., 1993)], 
recently available in two identical parallel models (TWIN-SHIME (Van den Abbeele et al., 
2010)), is a composite system consisting of five double-jacketed vessels of various 
volumes, each replicating a particular part of the gastrointestinal microbial ecosystem. It 
simulates the stomach and the small intestine with two vessels of 0.3 L, and the large 
intestine with three vessels reproducing three compartments at constant volume and with 
pH control.  
A second system was developed by the TNO in Holland, with several types and two 
functions. The TIM-1 (TNO Intestinal Model 1) is an in-vitro model of the upper part, with 
compartments replicating the stomach and the three parts of the small intestine (duodenum, 
jejunum and ileum) (Minekus et al., 1999). This is mainly achieved by a simulation of the 
saliva flow, gastric and pancreatic juices, and the peristaltic mixing of the chyme. Physical 
and chemical factors such as the transit time, temperature and pH control, and removal of 
digested compounds using hollow fibre membranes, are also used. This model seems useful 
for studying what happens to macro/micro-nutrients and the survival/stability of 
probiotics in the upper part of the GIT. A second TIM (TIM-2 for TNO Intestinal Model 2) 
simulates the colon, by controlling pH, anaerobiosis, and the gradual intake of media, as it 
would be with the upper part metabolism of food (Rajilic-Stojanovic et al., 2010; van der 
Werf & Venema, 2000).  
The final model was also developed in Europe, by the laboratories of George Macfarlane 
and Glenn Gibson in the United Kingdom (Macfarlane & Gibson, 1998). It is based on a 
compartmentalized system for simulating the different parts of the human colon (proximal, 
transverse and distal). An anaerobic continuous culture system is distributed among the 
different compartments and simulates the continuity of the colon. Our three-stage system 
(3S-ECSIM) is strongly inspired by this equipment, and is based on the same principles, 
except for maintaining anaerobic conditions.  
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These systems, however, do not integrate the epithelial, neuroendocrine and immune host 
components, but can include means for simulating bacterial biofilms such as those observed 
on the colonic epithelium or the food in transit (Macfarlane & Macfarlane, 2007). 
 
Core Medium 
Trace elements solution 
1 mL per L of core 
medium 
Vitamin solution 
1 mL per L of core medium 
Elements g.L-1 Elements mg.L-1 Elements mg.L-1 
Mucin 
Starch 
Pectin 
Guar gum 
Xylan 
Arabinogalactan 
Inulin 
Cystein 
Casein 
Peptone 
Tryptone 
Yeast extract 
Bile salts 
Tween 80 
Fe2SO4. 7H2O 
NaCl 
KCl 
KH2PO4 
MgSO4. 7H2O 
CaCl2. 6H2O 
NaHCO3 
Hemin 
pH adjusted to 6.0 
4.0 
5.0 
2.0 
1.0 
2.0 
2.0 
1.0 
0.8 
3.0 
5.0 
5.0 
4.5 
0.4 
1.0 
0.005 
4.5 
4.5 
0.5 
1.25 
0.15 
1.5 
0.05 
 
MnSO4. 2H2O 
FeSO4. 7H2O 
CoSO4 
ZnSO4 
CuSO4. 5H2O 
AlK(SO4) 
H3BO3 
Na2MoO4. 2H2O 
NiCl2. 6H2O 
Na2SeO3 
500 
100 
100 
100 
10 
10 
10 
10 
100 
10 
Menadione 
d-biotin 
Pantothenate 
Nicotinamide 
Vitamin B12 
Thiamin 
 
para-aminobenzoic 
acid 
1 
2 
10 
5 
0.5 
4 
 
5 
 
Table 2. Composition of the artificial gut medium 
This medium is derived from those previously described (Macfarlane et al., 1998; Molly et 
al., 1993) and is a mix of three solutions: a trace elements solution, a vitamin solution (1 mL 
of each for 1 L of artificial gut medium) and the core-medium. 
3.2 General description of the ECSIM  systems  
To complete these in-vitro systems, we have developed our own infrastructure to simulate 
the human colon, with the goal of having a modular system for maintaining a human 
microbiota in similar environmental conditions to those encountered physiologically and 
pathologically in the human gut. This system was developed with the technical support of 
Global Process Concept (France, see www.gpcbio.com for more information). It consists of 
three bioreactors which can operate independently, but also may be associated (see the next 
chapter 3.3). It is possible to supply each bioreactor with an identical nutritive medium from 
a unique tank or to supply each with a different medium. The usual medium faithfully 
replicates the contents of the terminal ileum from an individual with a Western diet, as 
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described by several groups (Macfarlane et al., 1998; Molly et al., 1993). This basal medium 
is shown in Table 2. If required, it can be modified to simulate other systems or to simulate 
specific cases, such as the uptake of prebiotics, the excessive presence of protein residues 
due to poor hydrolysis/absorption in the anterior parts, or an excess of bile acids, ...  
 
 
Fig. 3. Description of one module of the ECSIM, a GPC™ bioreactor. 
A- Schematic representation of the tank and connections. B- General view of the complete 
module, command system and the heating/cooling water system  (behind).  
C- Detailed view of the bioreactor. 
Each modular system is based on a bioreactor that can operate autonomously if necessary 
(Figure 3). Each bioreactor is composed of a tank and an upper plate. The 2-L tank is made 
from borosilicated glass, mounted on a removable stainless steel frame. Its minimum useful 
volume is 0.5 L, however, it is used in all our different ECSIM variants with a volume of 1L. 
The tank has a jacket permitting the circulation of water from its own heating module (tank 
with electric heater and circulating pump) to maintain the temperature of the culture. The 
top plate (stainless steel) has various ports and accessories allowing the use of an agitation 
motor, an aeration at the tank bottom through a removable sparger, and a gas outlet 
equipped with a stainless steel condenser (for a max flow of 15 L/min) with an expansion 
chamber and internal coil for circulating cold water. The stirring inside the tank is made in a 
pendular motion using a Rushton turbine and a marine propeller (each with a diameter of 
60 mm) with adjustable height on the stirrer shaft. The system incorporates a temperature 
sensor, pH electrode, redox electrode, a liquid level or foam (modular) sensor, and an 
injection input for pH correction (which can be used for the substrate). The plate has a sterile 
pH/Redox probe
Sparger
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2M NaOH control
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Water in
Water on
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B
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sampling device for sterile medium inoculation, addition and sampling. Each bioreactor has 
its own control terminal connected to a PC via an Ethernet cable. Dedicated software is used 
to control the stirring speed (variable from 40 to 1000 rpm), temperature, pH, ORP and the 
level regulations and measurements. In parallel, the terminal controls four peristaltic pumps 
(to ensure the addition of nutrient solutions, neutralizing solutions and tests) and valves to 
automatically control the gas flow. The dedicated software (using Windows™) allows a 
hierarchical control of experiments (4 levels), ranging from single view measurement tables 
in real time without the possibility of intervention through access, to full functionality 
(detailed configuration and complete opportunity to exit the software and turned off the 
set). 
3.3 Coupling/associating ECSIMs to generate other in vitro systems  
The following describes the use of ECSIM as a chemostat, although sometimes it may be 
(and is) used for batch cultures. One of the advantages of the ECSIM system is its 
modularity which allows a variety of different applications using the same components. 
Our approach consists of three initial modules which can produce three different 
scenarios depending on their settings (Figure 4). The first case considers these three 
systems as being totally independent, with each bioreactor having its own experiment 
controls (left, Figure 4).  
This approach provides rapid responses to various issues. If the effect of a component (biotic 
or abiotic) on the particular microbiota of different individuals has to be addressed, each 
bioreactor is inoculated with a particular microbiota, and as experimental conditions are 
identical, the incubation medium is shared between the different systems. If the experiment 
concerns the dose-effect or formulation of a compound, each bioreactor is started with 
strictly identical conditions (culture medium, inoculum, pH,…), with each bioreactor pump 
providing a controlled release of different amounts of the compound from the same stock 
solution. Other alternatives can be implemented using the same principle. In these cases, the 
proper control of each bioreactor is provided by a comparison test carried out before, 
between and after any modification is made. Controls are sampled after obtaining stability, 
which is considered acceptable after at least 5-times the retention time of the medium in the 
bioreactor. The experimental measurements are then retrieved either kinetically, during the 
addition (progressive or not) of the compound, or after re-obtaining a new state of 
equilibrium, or both. The results can be complementary and depend on the desired 
information, the disruption of the system itself (specific metabolites of this phase, 
responsible mechanisms, ...) or the final long-term effect of waiting for the new induced 
equilibrium.  
It is possible that the extreme sensitivity of these systems limits the comparisons which 
can be made between the different bioreactors and experiments. The apparatus, however, 
is designed to severely limit any technical disruption when working on the bioreactor 
(especially sampling). Another possible problem is confirming that the observed effect in 
a test does not result from a deviation of the system over time, independently from the 
test being performed. The realisation of a witness test and two bioreactor tests (see Figure 
4, centre diagram) overcomes this problem by performing a co-inoculation of the three 
systems at T0, and by comparing these different samples for each bioreactor at different 
times (during the supposed equilibrium phase in the control, during the disturbance 
conducted in parallel on two bioreactors, during the equilibrium phase resulting from the 
disturbance, ...). 
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Fig. 4. The ECSIM paradigm: the modular components allow various organizations and 
various applications with identical elements from Global Process Concept. 
Finally, the modularity of the system can be broken down as a grouping of bioreactors, 
ensuring continuity in the transition from a medium (and microbiota) from a medium stock, 
to a first bioreactor, then to a second, up to a third. The advantage of this system is the 
ability to modify the experimental conditions in each of the bioreactors. In all cases the 
experimental periods are long, extending up to several days in the last case presented. The 
duration time of a system disruption, therefore, is usually limited to a few seconds for a 
single injection, or a few hours for an incremental change.  The need to obtain a steady state 
requiring incubation times equal at least to 5 residence times, however, may lead to long 
experiment times. For example, if we consider that a basic transit-time in the colon is 48 
hours (nt, normal transit), and the length of the proximal colon being about 26% of the entire 
colon (vs 37% for each other of transverse and distal parts), we obtain around 13 hours of 
transit, only in the proximal part (Table 3). Therefore, a delay of 65 hours (nearly 3 days) is 
needed to reach a stabilised state. Furthermore, the transit time should be increased to 
nearly 18 hours in a transverse or a distal compartment, leading to a delay of 90 hours 
(almost four days) to obtain a steady state. Finally, the delay for two steady states separated 
by a disturbance (obtaining the first steady state/disturbance/result at stabilization) is, 
therefore, about a week for an experiment conducted in ntP-ECSIM (normal transit 
Proximal-ECSIM) and is two weeks for an experiment conducted in stP-ECSIM (slow transit 
Proximal-ECSIM, simulating a slow transit time of 96 hours for the colon).  
3 parallels and
independant experiments
2 parallels vs
One control
Example of use
- Three different inoculi, three different conditions
- Three different inoculi, one simple condition
- One simple inoculum, three different conditions
- One simple inoculum, one simple condition x3
each experiment being its own control 
P-ECSIM (environmental conditions of the Proximal part of the colon) 3S-ECSIM (Three stage ECSIM)
T(ransversal)-ECSIM, D(istal)-ECSIM,… st 3S-ECSIM (with a Slow-Transit simulation)
stP-ECSIM (Slow-Transit simulation of the Proximal part) nt 3S-ECSIM (with a Normal-Transit simulation)
ntP-ECSIM (Normal-Transit),… simulating a complete gut with its proximal, transversal and distal part
…
1 unique apparatus
with 3 different associated vessels, each with
its own condition, continuously fed
example
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When placed in a continuous 3-stage system (3S-ECSIM) to replicate the entire colon in these 
three functional parts, the completion time of the experiment increases accordingly, each 
state is expected to be stabilized individually and progressively. For example to simulate a 
48-hours transit time, 10 days are needed to get a steady state in the last compartment (the 
distal part), and, as previously mentioned, the system was already stable in the first 
bioreactor (simulated proximal part) after 3 days. Therefore, if the effect of a disturbance is 
studied on the balance of the microbiota, the experiment will take approximately 20 days.  
Another consequence would be the minimum doubling time that any microorganism must 
have to be kept in the reactor. If the time is greater than this minimal value, the 
microorganism will not be kept in the bioreactor but will be lost through the dilution effect. 
Table 3 indicates these values for of our system for various cases.  
The working volume of each reactor is maintained at 1 L in order to lower the disturbance of 
the system by the sample intake itself. This means, however, that about 2 L of medium is 
needed to feed one chemostat bioreactor per day for a normal transit time simulation: either 
a P-ECSIM alone or a 3S-ECSIM composed of three vessels. This volume is naturally 
reduced twice while increasing the simulated transit time to a 96-hour simulation (Table 3).  
 
Residence Time 
(h) 
Dilution Rate1 
(h-1) 
Feed rate2 
(vol=1L) 
(mL.min-1) 
Medium 
 
(L per days) 
Minimum 
doubling time3 (h) 
A-Simulation of a 48-h transit time (nt)   
12.48 0.0801 1.3355 1.9231 8.65 
17.76 0.0563 0.9384 1.3514 12.31 
17.76 0.0563 0.9384 1.3514 12.31 
B-Simulation of a 96-h transit time (st)   
24.96 0.0401 0.6677 0.9615 17.30 
35.52 0.0282 0.4692 0.6757 24.62 
35.52 0.0282 0.4692 0.6757 24.62 
1the dilution rate is calculated as the inverse of the residence time. 
2in this case, the feed rate corresponds directly to the dilution rate, due to the 1-L volume. 
3the minimum doubling time corresponds to the minimum period in which a microorganism should 
divide, in order to not be washed by dilution effect: obtained by dividing ln2 by the dilution rate. 
Table 3. Characteristics of the dilution rate, feed rate, volume of media needed and the 
minimal doubling time for simulating the indicated residence time. A working volume of 1L in 
each vessel, in order to simulate a normal transit time (A, 48h) or a slow transit time (B, 96h). 
3.4 Coupling/associating analytical systems 
The ECSIM system is actually a very powerful sample generator because of the different 
controls it can perform. It can test the metabolic activity of microbiota in realistic terms, 
influenced by typical environmental constraints which may be encountered in humans, 
whether physiological or pathological or concerning functional, nutritional or other situations. 
It provides in vitro testing of the impact of a living, or an abiotic element, on the constitution 
and metabolism of a microbiota. It is  a valuable tool, but has little or no interest if it is not 
coupled with an analytical infrastructure, particularly concerning the microbial, biochemical 
and molecular fields. Figure 5 shows what we feel to be the most important analyses.  
Firstly, the analytical platform has to establish a quick inventory of the main microbiological 
and biochemical components. Classic microbiology, despite its limitations, especially in this 
www.intechopen.com
 Applied Biomedical Engineering 76
particular anaerobic ecosystem, remains of great help in identifying and enumerating total 
anaerobes, facultative anaerobes, and functional groups and/or some genus (bifidobacteria, 
lactobacilli, Bacteroides spp,...).  
 
 
Fig. 5. Example of some analyses and their use to address questions about the gut biology 
from experiments developed from the ECSIM.  
Anaerobic microbiology is technically easier when an anaerobic chamber is used. From a 
biochemical point of view, special importance is given to nutritional compounds (sugars, 
lipid and total proteins assays) and also to the major metabolites, such as those issuing from 
the fermentation process: gases (H2, CO2 , H2S, ...), lactic acid and short chain fatty acids. 
Gases can be detected and quantified using several methodologies, including Gas 
Chromatography (GC), and the other elements mainly by High Precision Liquid 
Chromatography (HPLC). If these elements are essentials, however, other more global 
approaches are now possible which provide a wealth of consistent information about 
microbial metabolites and microbes. At the metabolic level, therefore, a metabolomic 
approach will determine real metabolic identity cards before and after the testing, associated 
clearly with identified microbial populations.  
Working with the platform “exploration du metabolism” from the Clermont-Theix INRA 
centre (the French National Institute for Agronomic Research), we can already identify 
metabolic fingerprints and compare experiences between two situations (Feria-Gervasio et 
al., 2010). Using the same principle, global (comprehensive) approaches for determining 
microbial diversity are also in progress. For reasons of cost and speed, it uses an approach 
giving a more informational fingerprint. We usually perform the RISA techniques 
Samples
(steady-state, stress, 
kinetics,…)
Microbiological studies
16S analysis (sequencing, DNA Chips,…)
Metagenomics,…
Enzymatic assay, 
CPG, HPLC, LC-MS,…
Metabolomics
mRNA expression chips, Q-RT-PCR
Proteins (Enzymes,…)
media, 
pre-pro-synbiotics, 
conditions (transit time, 
pH, …)
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(ribosomal intergenic spacer analysis, (Cardinale et al., 2004)) in order to obtain comparable 
fingerprint samples: Figure 6 shows an example. When necessary, rather than using 
pyrosequencing analysis of 16S rDNA banks, we use a phylogenetic DNA microarray called 
HuITMiCHIP. This biochip, which is presently being validated, was developed in 
collaboration with the laboratory of Pr Pierre Peyret (GIIM, UMR UBP-CNRS 6023, 
Clermont-Ferrand). It has about 5,000 specific oligonucleotides probes designed for 
detecting 67 bacterial families present in the human GIT. Depending on the method used, it 
provides a thorough determination of diversity associated with a semi-quantitative 
evaluation of populations (William Tottey, personal communication). The most interesting 
data can then be verified by quantitative PCR tools. In the near future we hope to be able to 
associate metabolic and microbial diversity data to expression analysis concerning 
quantitative changes of bacterial mRNAs expression, when studying an induced metabolic 
disturbance (Figure 5). 
As a general example, Figure 6 shows an experiment conducted with P-ECSIM studying the 
impact of transit time on the nature and metabolism of the microbiota. The experiment was 
initiated from a faecal slurry at 20% (w/v) cultured at 37° C in several successive anaerobic 
batch with the colonic medium (Table 2), and then stored at -20°C as aliquots at 20% 
glycerol (v/v). One of these aliquots was unfrozen on ice and used to inoculate a preculture 
of 5 mL of artificial gut medium, grown at 37°C for 10 hours. It was then transferred for 15 
hours into a 1L Erlenmeyer flask containing 95 mL of artificial gut medium. This was then 
transferred into 900 mL of complete artificial gut medium in two stirred 2-L tank 
bioreactors, previously N2-flushed, for a 24-hour batch culture. A continuous cultivation 
was subsequently launched in parallel in the two bioreactors. The initial dilution rate was of 
D=0.08 h-1, followed by D=0.04 h-1 (Figure 6-A). A dilution rate of 0.08 h-1 simulates a transit 
time in the proximal colon equivalent to 12.5 hours, i.e. a colonic transit time of about 48 
hours, which is considered normal (ntP-ECSIM, normal transit time Proximal-ECSIM ) (see 
Table 3). Conversely, a dilution rate of 0.04 h-1 simulates a slow colonic transit time in 
proximal condition, approximately 25 hours (stP-ECSIM, slow transit time Proximal 
ECSIM), equivalent to a global gut transit of 96 hours. Controlling the pump allows for 
deceleration and acceleration (c=0.0025 h-1), providing a gradual change from one state to 
another in a few hours. The C-BIO (Global Process Concept inc., France) acquisition and 
control software was used to adjust the stirring rate at 400 rpm, maintain the temperature at 
37° C, and the pH at 5.75 by automatic addition of NaOH. The ORP was monitored every 5 
minutes using an Argenthal reference probe from Mettler Toledo (3253i/SG/225 Inpro® 
probe). Samples were taken over each steady state, mimicking either a normal transit (nt, 
states 1 and 3) or a slow transit (st, state 2). As presented in Figure 6-B and C, the microbial 
metabolism and its diversity were affected by this modification of retention time (Feria-
Gervasio et al., 2010). The part B highlights the variation of the diversity of the microbiota 
using the RISA (Ribosomal Intergenic Spacer Amplification). This technique (Cardinale et al. 
2004) provides a rapid comparison of conserved and modified patterns. In Figure 6-C, a 
PCA (Principal Components Analysis) is shown, deduced from the metabolomic data 
retrieved from the LC-MS analysis. It indicates that the samples may all be differentiated by 
their origins, either the raw artificial gut medium, the ntP or the stP- ECSIM (E Pujos, JF 
Martin and JL Sebedio, personal communication). These results also indicate that there are 
fewer differences among samples from the same steady-state, highlighting the real stability 
of the so-called steady-state. Moreover, they also indicate that results are very similar 
between reactors used in the same conditions. 
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Fig. 6. An example of the use of the ECSIM system: an experiment in P-ECSIM addressing the 
question of effect of the transit time on the microbial diversity and its metabolism. 
A- Design of the experiment, with the modulation of the dilution rate in order to simulate a 
normal (nt P-ECSIM, 48h) or a slow (st P-ECSIM, 96h) transit in the proximal part of the 
colon.B- Fingerprints obtained from the RISA experiments, showing the impact of the 
retention time (i.e. the transit time) on the proximal gut microbiota studied in P-ECSIM. C- 
PCA analysis of the metabolites detected by LC-MS (courtesy of E Pujos, JF Martin and JL 
Sebedio), highlighting the different metabolic status when changing the residence time, and the 
similar metabolic fingerprint obtained with two different bioreactors in the same conditions. 
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4. Conclusion 
Studying the role of human microbiota in the digestive tract remains difficult because of 
various technical and ethical problems, however, in-vitro systems may overcome some of 
them. We have shown that the ECSIM system proposes a modular and adaptable solution 
when focusing only on the metabolic behaviour of the microbiota per se, without addressing 
its cellular and metabolic interaction with the host. The system can be seeded by a faecal 
microbiota, even to simulate a proximal part, or the whole 3 parts, making it easier 
technically and ethically throughout the experimentation. 
The ECSIM system also helps to mitigate the causes of fluctuations among experiments, due 
to strict control of parameters. It, therefore, provides an effective means of helping us better 
understand the role of the human intestinal microbiota, and the role and fate of endogenous 
and exogenous factors (physico-chemical, nutrients, prebiotics, probiotics, synbiotics, ...). 
The future development of in-vitro systems, including human intestinal cells (epithelial, 
immune cells), would be of very great interest, but for the time being remains too technically 
difficult to undertake. This kind of apparatus, therefore, may also provide a means for safely 
producing a human microbiota to be reintroduced into a human GIT. This process could be 
of great interest for several pathologies (for example, Clostridium difficile diarrhoea), using 
a faecal bacteriotherapy  (Bakken, 2009; Borody et al., 2004) provided by a specially designed 
in vitro production system. 
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